Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations (Unaudited)

v3.10.0.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Income Statement [Abstract]        
Revenues
Costs and expenses:        
General and administrative costs, including $784,390 and $12,000 to related parties for the three months ended September 30, 2018 and 2017, respectively, and $808,390 and $41,691 to related parties for the nine months ended September 30, 2018 and 2017, respectively 1,030,929 257,542 1,715,837 1,013,280
Research and development costs, including $804 and $40,225 to Theradex for the three months ended September 30, 2018 and 2017, respectively, and $804 and $104,840 to Theradex for the nine months ended September 30, 2018 and 2017, respectively 3,454 205,674 70,249 363,476
Total costs and expenses 1,034,383 463,216 1,786,086 1,376,756
Loss from operations (1,034,383) (463,216) (1,786,086) (1,376,756)
Interest income 424 797 1,547 961
Net loss $ (1,033,959) $ (462,419) $ (1,784,539) $ (1,375,795)
Net loss per common share - basic and diluted $ (0.02) $ (0.01) $ (0.03) $ (0.02)
Weighted average common shares outstanding - basic and diluted 58,029,292 58,016,031 58,026,986 55,073,250